Oregon Health & Science University.
University of Texas Medical School at Houston.
Pediatr Blood Cancer. 2018 Aug;65(8):e27074. doi: 10.1002/pbc.27074. Epub 2018 Apr 18.
In the United States, adolescent and young adult (AYA) patients with cancer have the lowest clinical trial participation rate of all age groups and slower progress in survival improvement than younger patients. Ominously, AYA clinical trial participation has been steadily decreasing since 2010, except in 15-19 year olds and AYAs with acute lymphoblastic leukemia. In order to reverse the accrual trend, multiple changes are necessary, including convincing community oncologists to pursue clinical trials on behalf of their AYA patients and to have the new National Community Oncology Research Program and National Clinical Trials Network lead a coordinated effort to increase accrual.
在美国,癌症青少年和年轻成人(AYA)患者的临床试验参与率是所有年龄组中最低的,且其生存率的改善速度比年轻患者更慢。令人担忧的是,自 2010 年以来,AYA 临床试验的参与率一直在稳步下降,除了 15-19 岁的患者和急性淋巴细胞白血病的 AYA 患者。为了扭转入组趋势,需要进行多项变革,包括说服社区肿瘤医生代表 AYA 患者开展临床试验,并让新的国家社区肿瘤学研究计划和国家临床试验网络牵头协调努力,以增加入组人数。